Exploring relationships between first-line nurse manager's safety attitudes and safety factors in Henan, China

被引:9
|
作者
Zhang, Feng [1 ]
Tian, Li [2 ]
Shang, Xiaoping [3 ]
Li, Xiang [2 ]
Xue, Rui [2 ]
Cheng, Shuhua [1 ]
Chen, Changying [4 ]
机构
[1] Zhengzhou Univ, Dept Rheumatol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
[2] Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
[3] Zhengzhou Univ, Dept Med Record, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
[4] Zhengzhou Univ, Affiliated Hosp 1, Coll Nursing, Zhengzhou, Henan, Peoples R China
关键词
Chinese hospital; first-line nurse manager; nursing; safety attitudes questionnaire; safety culture; INTENSIVE-CARE-UNIT; EDUCATIONAL-LEVELS; PATIENT MORTALITY; CULTURE; LEADERSHIP; OUTCOMES; PERCEPTIONS; HOSPITALS;
D O I
10.1111/jonm.12549
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
Aim: To examine first-line nurse managers' perceptions of safety culture and explore relationships between their safety attitudes and safety factors in Henan Province, China. Background: Health providers' perceptions of patient safety culture have been studied widely, but little is known about first-line nurse managers' safety attitudes. Methods: A cross-sectional survey was conducted with a convenience sample of 823 first-line nurse managers in 216 hospitals across Henan Province, China. The Safety Attitudes Questionnaire (Chinese version) was distributed to first-line nurse managers during training meetings; responses were returned in a sealed envelope in person or by mail. ANOVAs were used to analyse the differences in Safety Attitudes Questionnaire (Chinese version) scores between first-line nurse managers' attitudes and safety factors. Results: The mean scores across the six domains of Safety Attitudes Questionnaire (Chinese version) ranged from 56.6 to 79.4 on a 100-point scale. First-line nurse managers: 45years of age perceived better safety climate (p<.05); those with higher professional ranks and medical centre positions reported higher mean scores for teamwork climate (p<.01) and stress recognition (p<.01); and those with baccalaureate degrees or higher had significantly higher mean scores for stress recognition (p<.01). Conclusion: First-line nurse managers' safety attitudes were not satisfactory and there is great potential to improve patient safety culture. Age, hospital level, educational background and professional rank are positively related to first-line nurse managers' attitudes.
引用
收藏
页码:314 / 320
页数:7
相关论文
共 50 条
  • [41] Efficacy and safety between first-line therapies in metastatic castration-resistant prostate cancer in combination in the PARPi and ARSI era: A systematic review and network meta-analysis.
    Guo, Xuanjun
    Li, Yixin
    Wang, Mengying
    Peng, Hexiang
    Guo, Huangda
    Hou, Tianjiao
    Zhang, Hanyu
    Jiang, Jin
    Sheng, Tao
    Fan, Yu
    Wu, Tao
    He, Zhisong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [42] Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients
    Ma, Yilong
    Zhao, Chang
    Zhao, Hui
    Li, Haiping
    Chen, Changyong
    Xiang, Hua
    Zheng, Chuansheng
    Ma, Cong
    Luo, Chao
    Qiu, Huaiming
    Yao, Yuanhui
    Hu, Hongyao
    Xiong, Bin
    Zhou, Jun
    Zhu, Hui
    Long, Qingyun
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (12): : 7456 - 7470
  • [43] Efficacy and Safety of Chemotherapy or EGFR-TKIs as First-Line Therapy in NSCLC Patients Harboring Non-Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
    Liao, Chen
    Bai, Li
    He, Tingting
    Liang, Qingle
    Hu, Defeng
    Lei, Shipeng
    He, Yong
    Wang, Yubo
    CANCER MEDICINE, 2025, 14 (01):
  • [44] Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
    Zhu, Chengpei
    Li, Hu
    Yang, Xiaobo
    Wang, Shanshan
    Wang, Yunchao
    Zhang, Nan
    Wang, Yanyu
    Xue, Jingnan
    Zhang, Longhao
    Ning, Cong
    Yang, Xu
    Xun, Ziyu
    Chao, Jiashuo
    Long, Junyu
    Sang, Xinting
    Zhu, Zhenyu
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2949 - 2960
  • [45] Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
    Chengpei Zhu
    Hu Li
    Xiaobo Yang
    Shanshan Wang
    Yunchao Wang
    Nan Zhang
    Yanyu Wang
    Jingnan Xue
    Longhao Zhang
    Cong Ning
    Xu Yang
    Ziyu Xun
    Jiashuo Chao
    Junyu Long
    Xinting Sang
    Zhenyu Zhu
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2023, 72 : 2949 - 2960
  • [46] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [47] A phase II multicenter trial assessing the efficacy and safety of first-line S-1 thorn ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701
    Kobayshi, Kazuma
    Suyama, Koichi
    Katsuya, Hiroo
    Izawa, Naoki
    Uenosono, Yoshikazu
    Hu, Qingjiang
    Kusumoto, Tetsuya
    Otsu, Hajime
    Orita, Hiroyuki
    Kawanaka, Hirofumi
    Shibao, Kazunori
    Koga, Satoshi
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Oki, Eiji
    Baba, Hideo
    Mori, Masaki
    EUROPEAN JOURNAL OF CANCER, 2022, 166 : 279 - 286
  • [48] HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment
    Ito, K.
    Yuki, S.
    Nakano, S.
    Yagisawa, M.
    Sawada, K.
    Ishiguro, A.
    Muto, O.
    Hatanaka, K.
    Okuda, H.
    Sato, A.
    Sasaki, Y.
    Nakamura, M.
    Sasaki, T.
    Kobayashi, T.
    Dazai, M.
    Nakatsumi, H.
    Ueda, A.
    Tateyama, M.
    Sogabe, S.
    Matsumoto, R.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S108 - S108
  • [49] A randomized phase III study to compare efficacy and safety between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10)
    Choi, I.
    Lee, K-W.
    Zang, D. Y.
    Ryu, M. H.
    Han, H. S.
    Kim, K. H.
    Kim, M-J.
    Koh, S. A.
    Lee, S. S.
    Koo, D-H.
    Ko, Y. H.
    Sohn, B. S.
    Park, J. H.
    Kim, J. W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1041 - S1041
  • [50] Ef ficacy and Safety of Anti -Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People 's Republic of China: a Systematic Review and Meta-Analysis
    Chen, Qi-An
    Ma, Kai
    Zhang, Lin
    Lin, Wei-Hao
    Wu, Xian-Xian
    Gao, Yi-Bo
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (06):